Post

Chris Bahl
@cdbahl.com

We signed a new research collaboration and license agreement! @aiproteins.com will design and optimize de novo #miniproteins to multiple targets, and Astellas Pharma will do development & commercialization. This division of labor will help get new medicines to patients with the urgency they deserve.

Endpoints News@endpts.com

Exclusive: Astellas struck a deal with AI Proteins that could top $400M, betting on the startup’s AI-designed miniproteins.

endpoints.newsExclusive: Astellas partners with Boston ‘miniproteins’ startupAstellas partners with AI Proteins, paying up to $400M, to develop miniprotein therapies using AI. CEO Chris Bahl targets TNFR1 and multi-target cancer treatments.

4 reposts8 likes

No replies yet.